WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 465904
CAS#: unknown
Description: PSB-11 is a A3AR antagonist.
MedKoo Cat#: 465904
Name: PSB-11
CAS#: unknown
Chemical Formula: C16H17N5O
Exact Mass: 295.1433
Molecular Weight: 295.346
Elemental Analysis: C, 65.07; H, 5.80; N, 23.71; O, 5.42
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: PSB-11; PSB11; PSB 11;
IUPAC/Chemical Name: (R)-8-ethyl-4-methyl-2-phenyl-1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purin-5-one
InChi Key: RGDHRCXUMURWBJ-LLVKDONJSA-N
InChi Code: InChI=1S/C16H17N5O/c1-3-11-9-21-15(17-11)12-14(20(2)16(21)22)19-13(18-12)10-7-5-4-6-8-10/h4-8,11H,3,9H2,1-2H3,(H,18,19)/t11-/m1/s1
SMILES Code: CC[C@H]1N=C2C3=C(N=C(C4=CC=CC=C4)N3)N(C)C(N2C1)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 295.346 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Bouzo-Lorenzo M, Stoddart LA, Xia L, IJzerman AP, Heitman LH, Briddon SJ, Hill SJ. A live cell NanoBRET binding assay allows the study of ligand-binding kinetics to the adenosine A3 receptor. Purinergic Signal. 2019 Jun;15(2):139-153. doi: 10.1007/s11302-019-09650-9. Epub 2019 Mar 27. PMID: 30919204; PMCID: PMC6635573.
2: Kim SK, Gao ZG, Jeong LS, Jacobson KA. Docking studies of agonists and antagonists suggest an activation pathway of the A3 adenosine receptor. J Mol Graph Model. 2006 Dec;25(4):562-77. doi: 10.1016/j.jmgm.2006.05.004. Epub 2006 May 9. PMID: 16793299; PMCID: PMC6262875.
3: Müller CE. Medicinal chemistry of adenosine A3 receptor ligands. Curr Top Med Chem. 2003;3(4):445-62. doi: 10.2174/1568026033392174. PMID: 12570761.
4: Gao ZG, Suresh RR, Jacobson KA. Pharmacological characterization of DPTN and other selective A3 adenosine receptor antagonists. Purinergic Signal. 2021 Dec;17(4):737-746. doi: 10.1007/s11302-021-09823-5. Epub 2021 Oct 28. PMID: 34713378; PMCID: PMC8677861.
5: Xia L, Kyrizaki A, Tosh DK, van Duijl TT, Roorda JC, Jacobson KA, IJzerman AP, Heitman LH. A binding kinetics study of human adenosine A3 receptor agonists. Biochem Pharmacol. 2018 Jul;153:248-259. doi: 10.1016/j.bcp.2017.12.026. Epub 2018 Jan 3. PMID: 29305857; PMCID: PMC5959751.
6: Gao ZG, Kim SK, Gross AS, Chen A, Blaustein JB, Jacobson KA. Identification of essential residues involved in the allosteric modulation of the human A(3) adenosine receptor. Mol Pharmacol. 2003 May;63(5):1021-31. doi: 10.1124/mol.63.5.1021. PMID: 12695530; PMCID: PMC4367541.
7: Gao ZG, Melman N, Erdmann A, Kim SG, Müller CE, IJzerman AP, Jacobson KA. Differential allosteric modulation by amiloride analogues of agonist and antagonist binding at A(1) and A(3) adenosine receptors. Biochem Pharmacol. 2003 Feb 15;65(4):525-34. doi: 10.1016/s0006-2952(02)01556-3. PMID: 12566079; PMCID: PMC8607904.
8: Gao ZG, Kim SG, Soltysiak KA, Melman N, IJzerman AP, Jacobson KA. Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives. Mol Pharmacol. 2002 Jul;62(1):81-9. doi: 10.1124/mol.62.1.81. PMID: 12065758; PMCID: PMC3953617.
9: Gao ZG, Jacobson KA. 2-Chloro-N(6)-cyclopentyladenosine, adenosine A(1) receptor agonist, antagonizes the adenosine A(3) receptor. Eur J Pharmacol. 2002 May 17;443(1-3):39-42. doi: 10.1016/s0014-2999(02)01552-2. PMID: 12044789; PMCID: PMC8358783.
10: Müller CE, Diekmann M, Thorand M, Ozola V. [(3)H]8-Ethyl-4-methyl-2-phenyl-( 8R)-4,5,7,8-tetrahydro-1H-imidazo[2,1-i]-purin-5-one ([(3)H]PSB-11), a novel high-affinity antagonist radioligand for human A(3) adenosine receptors. Bioorg Med Chem Lett. 2002 Feb 11;12(3):501-3. doi: 10.1016/s0960-894x(01)00785-5. PMID: 11814828.
11: Gao ZG, Van Muijlwijk-Koezen JE, Chen A, Müller CE, Ijzerman AP, Jacobson KA. Allosteric modulation of A(3) adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives. Mol Pharmacol. 2001 Nov;60(5):1057-63. PMID: 11641434; PMCID: PMC3953614.
